Z

Zeiss

Manufactures high-precision optical instruments and devices

Overview

Company Does Not Provide H-1B Sponsorship

ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.

Work here?Claim your company

About Zeiss

Simplify's Rating
Why Zeiss is rated
B
Rated A on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

HardwareIndustrial & ManufacturingHealthcareConsumer Goods

Company Size

5,001-10,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • November 2026 China approval for PT LUNANA opens myopia treatment in a massive market.
  • ZEISS launched CLINIC 360, ALTA DUO 300, and AT LUCIA 721P across 2026.
  • Bronwyn Brophy O'Connor starts December 1, 2026, bringing fresh Medtech operating discipline.

What critics are saying

  • June 2026 restructuring targets several hundred million euros savings and expects job reductions.
  • Kogent and Katalyst’s 2026 fraud and breach claims expose acquisition and integration risk.
  • Semiconductor geopolitics and slower growth forced ZEISS into cost cuts, threatening innovation execution by 2028.

What makes Zeiss unique

  • ZEISS owns end-to-end ophthalmic workflows, from diagnostics to surgical planning and treatment.
  • Its 2026 FDA-cleared CLINIC 360 and Surgery Planner deepen sticky cloud workflow integration.
  • ZEISS combines precision optics with semiconductor lithography heritage, creating hard-to-replicate engineering depth.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.1B

Above

Industry Average

Funded Over

0 Rounds

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Performance Bonus

Growth & Insights and Company News

6 month growth

0%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Nov 9th, 2026
ZEISS wins China approval for PT LUNANA lens to tackle myopia affecting 600M people

ZEISS Medical Technology has won approval from China's National Medical Products Administration (NMPA) for PT LUNANA, a phakic intraocular lens (pIOL) to treat myopia. The company showed the lens at the China International Import Expo in Shanghai. Wuxi Carl Zeiss Vision Pro Medical Technology, a ZEISS joint venture in China, developed the lens and will make it locally. It is the first in a planned family of ZEISS phakic lenses and comes in seven sizes. China has an estimated 600 million people with myopia. About 67.2% of those aged 15 to 19 are affected, and 9.5% have high myopia. ZEISS plans to launch the lens in China in 2027, then take it to other markets.

ZEISS
Oct 28th, 2026
ZEISS Ventures joins $2.2M round for Cambridge battery imaging spin-out Illumion

ZEISS Ventures has joined a £1.7 million funding round for Illumion, a University of Cambridge spin-out that builds imaging technology for battery research. Foresight Group, Cambridge Enterprise Ventures, Parkwalk, Cambridge Angels, and YourVC also took part. Illumion's charge photometry lets researchers watch individual battery particles as they charge and discharge. The company says this reveals processes inside working batteries that were previously out of reach. The money will fund commercialisation, product development, and work with researchers, battery makers, and industrial partners. That includes illumionONE, a real-time particle-level analysis system, and illumionX, a next-generation platform aimed at selected industrial uses.

Yahoo Finance
Oct 26th, 2026
Bronwyn Brophy O'Connor to lead Carl Zeiss Meditec as CEO from December 1, 2026

Bronwyn Brophy O'Connor, currently chief executive officer of Sweden's Vitrolife Group, will become CEO of Carl Zeiss Meditec AG on December 1, 2026. She will also join the Executive Board of Carl Zeiss AG, where she will lead the Medical Technology segment. She succeeds Andreas Pecher, who has served as interim CEO since January 1, 2026, alongside his role as chief executive of the ZEISS Group. Her appointment was first announced in May 2026. Brophy O'Connor has led Vitrolife since 2023. Her earlier roles include posts at Johnson & Johnson, Medtronic, and Thermo Fisher Scientific. Justus Wehmer will serve as chief financial officer of Carl Zeiss Meditec. The company generated revenue of €2,228 million in fiscal year 2024/25.

PR Newswire
Oct 22nd, 2026
ZEISS launches CT LUCIA 621P monofocal lens in Japan, expanding its Cataract Workflow

ZEISS Medical Technology has launched its CT LUCIA 621P monofocal intraocular lens (IOL) in Japan, adding it to the ZEISS Cataract Workflow. The company announced the move on October 22, 2026. The lens uses a proprietary asphericity concept to account for the natural misalignment between the cornea centre and the eye's optical axis. ZEISS says this supports consistent visual outcomes across a wide range of patients. It also has a reinforced optic-haptic junction and step-vaulted C-loop haptics, designed to ease centring and help keep the lens stable in the bag. ZEISS will show the lens at the 80th Annual Congress of Japan Clinical Ophthalmology in Kyoto from October 29 to November 1, 2026.

Associated Press
Oct 12th, 2026
ZEISS launches NLX X-ray inspection and DUNE wafer warpage correction for advanced chip packaging

ZEISS Semiconductor Manufacturing Technology (SMT) has launched two systems for advanced chip packaging: ZEISS NLX and ZEISS DUNE. The company announced them in San Francisco on October 12, 2026, as chips grow more complex. ZEISS NLX inspects the inside of chip packages without damaging them. It helps manufacturers spot defects in connections between stacked dies early, and it handles 300-millimetre wafers in both process development and high-volume production. ZEISS DUNE measures the topography of a wafer and corrects wafer bow individually. This helps avoid yield losses in downstream processing and prepares bonding processes. ZEISS SMT is showing the systems at SEMICON West, alongside its photomask tools. The company is also marking 100 years of business in the US in 2026.

Recently Posted Jobs

Sign up to get curated job recommendations

Zeiss is Hiring for 903 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs